This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.
Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Amarin (AMRN) Surges: Stock Moves 9% Higher
by Zacks Equity Research
Amarin (AMRN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin's (AMRN) Q3 Earnings Lag, Sales In Line, Stock Down
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the third quarter is attributable to continued demand for its cardiovascular drug, Vascepa. Generic competition for Vascepa seems imminent.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Amarin Loses Patent Appeal in Vascepa Lawsuit, Stock Dips
by Zacks Equity Research
Amarin (AMRN) receives a setback as the U.S. Court of Appeals upholds a ruling by Nevada district court in favor of the generic companies related to patent litigation against Vascepa.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Amarin (AMRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results
Aytu (AYTU) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.
Amneal (AMRX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will provide financial updates when it reports second-quarter 2020 results.
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amarin (AMRN) closed at $7.03, marking a +1.59% move from the previous day.
Implied Volatility Surging for Amarin (AMRN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Amarin (AMRN) closed at $6.92, marking a +0.58% move from the previous day.
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $6.78 in the latest trading session, marking a +0.89% move from the prior day.
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed the most recent trading day at $6.59, moving -1.35% from the previous trading session.
Why Amarin (AMRN) Stock Might be a Great Pick
by Zacks Equity Research
Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amarin (AMRN) closed at $6.68, marking a -1.18% move from the previous day.
Ultragenyx (RARE) Q1 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected first-quarter 2020 loss.
Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil
by Zacks Equity Research
Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.
Amarin's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Amarin.